Inovio Biomedical's DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for Hepatitis C
Inovio initiates 5th DNA vaccine clinical study: hepatitis C
The main purpose of the study is to show that the treatment is safe, but also to test if the treatment boosts patients' immune response to hepatitis C and its effects on virus replication.
"This is the first human study in the world in which a DNA vaccine against an infectious disease is being administered by in vivo electroporation. We are enthusiastic that enrollment has started as planned," said Jan Nilsson, CEO of Tripep AB.
The study encompasses a total of 12 treatment naive patients with chronic hepatitis C virus infections of genotype 1 and with a low viral load. The patients will be divided into four dose groups. Each patient will receive four monthly vaccinations and then be monitored for another six months.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.